Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
May 30 2024 - 8:30AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will
host informational booths, events, and presentations showcasing use
of its innovative TransCon technology in the areas of growth
hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and
Turner syndrome during ENDO 2024, the annual meeting of the
Endocrine Society being held June 1-4, 2024, in Boston.
“In addition to physician and caregiver presentations in
pediatric GHD, we look forward to our first in-person opportunity
to share data from foresiGHt, our pivotal trial of TransCon hGH in
adults with GHD,” said Aimee Shu, M.D., Ascendis Pharma’s Senior
Vice President of Clinical Development, Endocrine Medical Sciences.
“And with World Hypoparathyroidism Day coinciding with the first
day of ENDO, we are pleased to host an informational booth focused
on deepening physician awareness of the significant health and
quality-of-life impacts of hypoparathyroidism.”
Ascendis presentations during ENDO 2024 include:
Oral PresentationResults of the foresiGHt Trial Support the
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults with
Growth Hormone DeficiencyBeverly M.K. Biller, M.D.,
Massachusetts General Hospital and Harvard Medical School
- OR36-04 June 3, 2:45 – 3:00 p.m
ET.Ballroom 210B– BCEC
|
Product TheaterPerspectives on a Once-Weekly Growth Hormone
for Pediatric Growth Hormone DeficiencyPhilippe
Backlejauw, M.D., Cincinnati Children’s Hospital and University of
Cincinnati College of MedicineMike Gordon, Parent of a child living
with growth hormone deficiency
- S102-09June 2, 9:30 – 10:30 a.m.
ETScience Theater Exhibit Hall – Theater #2
|
Poster Presentation:Baseline Demographics and Design of the
SkybriGHt Registry Study. A US Multi-Center, Prospective,
Non-Interventional, Long-Term Effectiveness and Safety Study of
Children and Adolescents with Growth Hormone Deficiency Treated
with LonapegsomatropinPhilippe Backlejauw, M.D.,
Cincinnati Children’s Hospital and University of Cincinnati College
of Medicine
- Poster MON-198 June 3, 12:00 – 1:30
p.m. ETPoster Hall/Reception
|
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon technology platform to build a
leading, fully integrated biopharma company focused on making a
meaningful difference in patients’ lives. Guided by its core values
of Patients, Science, and Passion, Ascendis uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark and has additional
facilities in Europe and the United States. Please visit
ascendispharma.com to learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon technology platform to build a
leading, fully integrated biopharma company and (ii) Ascendis’ use
of its TransCon technologies to create new and potentially
best-in-class therapies. Ascendis may not actually achieve the
plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that Ascendis makes, including the
following: dependence on third party manufacturers, distributors
and service providers for Ascendis’ products and product
candidates; unforeseen safety or efficacy results in Ascendis’
development programs or on-market products; unforeseen expenses
related to commercialization of any approved Ascendis products;
unforeseen expenses related to Ascendis’ development programs;
unforeseen selling, general and administrative expenses, other
research and development expenses and Ascendis’ business generally;
delays in the development of its programs related to manufacturing,
regulatory requirements, speed of patient recruitment or other
unforeseen delays; Ascendis’ ability to obtain additional funding,
if needed, to support its business activities; the impact of
international economic, political, legal, compliance, social and
business factors. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Ascendis’ business in general, see Ascendis’ Annual
Report on Form 20-F filed with the U.S. Securities and Exchange
Commission (SEC) on February 7, 2024 and Ascendis’ other future
reports filed with, or submitted to, the SEC. Forward-looking
statements do not reflect the potential impact of any future
licensing, collaborations, acquisitions, mergers, dispositions,
joint ventures, or investments that Ascendis may enter into or
make. Ascendis does not assume any obligation to update any
forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo, and TransCon are trademarks owned by the Ascendis Pharma
group. © May 2024 Ascendis Pharma A/S.
Investor Contacts: |
Media
Contact: |
Tim Lee |
Melinda Baker |
Ascendis Pharma |
Ascendis Pharma |
+1 (650) 374-6343 |
+1 (650) 709-8875 |
tle@ascendispharma.com |
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
Patti Bank |
|
ICR Westwicke |
|
+1 (415) 513-1284 |
|
patti.bank@westwicke.com |
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From May 2024 to Jun 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Jun 2023 to Jun 2024